Division of Pharmacy Practice, School of Pharmacy and Health Sciences, Fairleigh Dickinson University, 230 Park Avenue, Florham Park, NJ, 07932, USA.
Division of Pharmaceutical Sciences, School of Pharmacy and Health Sciences, Fairleigh Dickinson University, Florham Park, NJ, USA.
J Cardiovasc Transl Res. 2020 Jun;13(3):463-477. doi: 10.1007/s12265-020-10024-5. Epub 2020 May 19.
Angiogenesis inhibitors, also known as vascular endothelial growth factor (VEGF) or vascular signaling pathway (VSP) inhibitors, have improved care of neoplastic diseases over the past decade. However, cardiovascular toxicities associated with these agents, such as hypertension and less commonly left ventricular systolic dysfunction and heart failure, have often been a limiting factor for continued use. Balancing the benefits of these agents with the associated toxicities is critical to ensure these therapies do not negatively impact oncological outcomes. The care of cancer patients with cardiovascular risks is challenging due to the heterogeneity of cardiovascular complications, paucity of evidence-based guidelines, and lack of channels for collaboration among healthcare providers. Herein, we provide a team-based approach for treatment of angiogenesis inhibitor-induced hypertension along with recommendations on monitoring and appropriate selection of anti-hypertensive agents.
血管生成抑制剂，也称为血管内皮生长因子（VEGF）或血管信号通路（VSP）抑制剂，在过去十年中改善了肿瘤疾病的治疗效果。然而，这些药物相关的心血管毒性，如高血压，以及不太常见的左心室收缩功能障碍和心力衰竭，往往是限制其持续使用的因素。平衡这些药物的益处和相关毒性至关重要，以确保这些治疗方法不会对肿瘤学结果产生负面影响。由于心血管并发症的异质性、循证指南的缺乏以及医疗保健提供者之间缺乏合作渠道，具有心血管风险的癌症患者的护理具有挑战性。在此，我们提供了一种基于团队的方法来治疗血管生成抑制剂引起的高血压，并就监测和适当选择抗高血压药物提出了建议。
